Soufflé Therapeutics raises $135.0M Series B (United States, Oct 2026)
Reach the investors backing rounds like this
Backed by Juvia Group, TCG Crossover Management +6 more · verified emails and LinkedIn on Datapile
Cell-Specific RNA Delivery Firm Soufflé Raises $135M Series B - Wowtale
Soufflé Therapeutics is developing cell-specific RNA delivery platforms to treat genetic diseases. Their REMEDY platform aims to deliver oligonucleotide therapies to specific cells outside the liver, addressing a key bottleneck in genetic medicine. This Series B funding will advance their lead programs targeting facioscapulohumeral muscular dystrophy (FSHD) and heart failure into clinical studies.
Cell-Specific RNA Delivery Firm Soufflé Raises $135M Series B Wowtale
| Oct 19, 2026 | Fortastra Corp. | $30.0M | Series A | United States |
| Oct 19, 2026 | Discovered Materials | $9.0M | Seed | United States |
| Oct 18, 2026 | TigerByte Cyber | $3.0M | Seed | United States |
| Oct 18, 2026 | North.cloud | $60.0M | Series B | United States |
22,153 investors back startups in United States
You just read who funded Soufflé Therapeutics. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.